MerLion Pharma is a leading natural product based research and development company headquartered in Singapore, with clinical development operations based in Berlin, Germany. The company is organised into two key business units, MerLion Research and MerLion Development.

MerLion Research is the company’s contract services business that has been created to exploit MerLion’s unique natural products discovery capabilities in the pharma, industrial biotechnology, agroscience, functional foods, flavourings, cosmetics and personal healthcare sectors. MerLion Research provides access to one of the world’s largest and most diverse natural product collections by offering sample/extract supply services, extract profiling and standardisation, assay development, highthroughput screening, compound purification and structural identification, biocatalyst isolation and strain improvement.

MerLion Development is progressing finafloxacin, a novel, highly differentiated antibacterial candidate, through Phase II clinical trials. The compound is being targeted initially for the eradication of Helicobacter pylori and treatment of urinary tract infections. In addition to finafloxacin, the company has a portfolio of earlier-stage, preclinical antibacterial and oncology programmes.